CSL plans to deliver more than six million doses of Afluria and the majority of the supply will be in single-dose, thimerosal-free, pre-filled syringes.
Afluria is indicated for the active immunization of persons aged 18 years and older against influenza caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria.
Paul Perreault, executive vice president of worldwide commercial operations at CSL Biotherapies, said: “CSL’s mission is to protect lives through vaccination, so we will continue to support educational and community efforts to increase vaccination rates in priority and at-risk US populations, such as healthcare workers, pregnant women and college students.”